Fibronectin type III and SPRY domain-containing protein 1 (FSD1)

Fibronectin type III and SPRY domain-containing protein 1 (FSD1) is a centrosome-associated protein characterized by the presence of a coiled-coil region downstream of a B-box (BBC) domain, a central fibronectin type III domain, and a C-terminal SPRY (splA and ryanodine receptor) domain[1][3][5]. FSD1 associates with specific microtubules and contributes to the stability and organization of microtubules during cytokinesis, and it plays a critical role in anchoring microtubule asters at centrosomes, which is important for ciliogenesis and proper embryonic development[1][2][5]. Its depletion impairs the assembly of the transition zone (TZ) during ciliogenesis. FSD1 is predominantly expressed in the brain and may be involved in neural function[1]. Aberrant epigenetic modification of its promoter has been linked to gastric carcinoma, providing a potential diagnostic biomarker, and FSD1-derived peptides may also serve as disease markers in brain tissue[1]. FSD1 is not a receptor, enzyme, transporter, or typical therapeutic target; it functions primarily as a microtubule-associated scaffold protein involved in cytoskeletal organization, ciliogenesis, and possibly neural processes[1][2][5]. No clinically relevant drugs are known to interact with FSD1, nor are there established mechanisms of action or safety concerns related to therapeutic targeting of this protein[5].

Other names

Fibronectin type III and SPRY domain containing 1GLFNDMIR1VLP27MGC3213MID1-related protein 1microtubule-associated protein GLFNDfibronectin type 3 and SPRY (spla, ryanodine) domain containing 1fibronectin type 3 and SPRY domain containing 1midline 1-related protein 1